Thursday, December 5, 2013
Publication and contact
Discoidin domain receptor tyrosine
In vitro studies suggest inhibiting DDR1 could help increase
the efficacy of chemotherapeutics in Hodgkin's lymphoma. In Hodgkin's
lymphoma cells, collagen from the tumor microenvironment induced DDR1
phosphorylation, and small interfering RNA against DDR1 increased cell
death of the collagen-treated cells compared with control siRNA. In
collagen-treated Hodgkin's lymphoma cells, overexpression of DDR1 protected
the cells from etoposide-induced cell death. Next
steps could include testing DDR1 inhibition in mouse models using
broad-spectrum receptor tyrosine kinase inhibitors such as Sprycel
dasatinib and Tasigna
nilotinib in combination with chemotherapeutics.
Co. and Otsuka Pharmaceutical
Co. Ltd. market Sprycel to treat chronic myelogenous
leukemia (CML) and acute lymphoblastic leukemia (ALL).
markets Tasigna to treat CML.
Etoposide is a generic topoisomerase
Published online Dec. 5, 2013
Patent and licensing status
Cader, F.Z. et al. Blood;
published online Oct. 17, 2013;
Contact: Fathima Zumla Cader, University of Birmingham, Birmingham,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]